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Progressive liver toxicity is a concern in HIV-infected
patients. Although liver biopsy remains the gold standard
for liver assessment, its invasiveness, sampling errors, var-
iability in interpretation and expense do not make it an
ideal routine follow-up exam. During the last decade, new
non-invasive tools have been developed for the assess-
ment of hepatic fibrosis in HCV and HIV/HCV co-infected
patients.
The aim of this cross-sectional study was to evaluate the
feasibility of transient elastography (TE) measuring liver
stiffness in chronically HIV-infected children. Inclusion
criteria were: materno-foetal transmission, age 8 to 18
years old, informed parental consent and patient assent.
Twenty-one HIV-1 chronically infected children were
included. There were 11 girls and 10 boys, with a median
age of 13.2 years (8.3–17.3). Five were HIV stage N, 3 were
stage A, 6 were stage B and 6 suffered from AIDS defini-
tion illness (stage C). For one orphan child HIV CDC sta-
tus could not be determined. Mean weight was 46.7 kg
(18.4–83.5), mean height was 151.2 cm (116–175).
Mean CD4 T-cell count at inclusion was 669 cells/mm3
(256–1,252) or 29.9% (9.4–45%), mean viral load was
3.88 log10 copies/mm3 (1.60–4.83). Eight children had
undetectable viral load (<40 copies/mm3). At the time of
enrolment, 10 patients received conventional HAART
with two NRTIs (nucleoside reverse transcriptase inhibi-
tor) and 1 PI (protease inhibitor), 4 received 2 NRTIs + 1
NNRTI (non-nucleoside reverse transcriptase inhibitor), 2
patients were on dual NRTI association, 1 was on triple
NRTI combination and 1 were receiving 1 drug of each
class (NRTI+NNRTI+PI). Three children were on planned
treatment interruption.
All patients underwent a Fibroscan exam. The two young-
est children failed in having a TE measure because of tech-
nical difficulties due to their small corpulence. The
average measurement success rate was 96.7%. HIV-
infected patients had significantly higher TE results than
matched healthy control children (5.92 +/- 1.60 versus
4.34 +/- 1.10 kPa) (p < 0.02). Furthermore, loss of elastic-
ity assessed by TE measures tended to increase with age in
a linear manner (adjusted R2: 0.208, p < 0.03). This cor-
relation was found only in the HIV-infected group. We
therefore hypothesized that HIV infection and/or contin-
uous exposure to antiretroviral treatment were responsi-
ble for this relation.
Our results showed that 1 – evaluation of liver stiffness is
feasible in most HIV-1 chronically infected children. 2 –
Patients had significantly higher TE results than matched
healthy control children 3 – the loss of elasticity tended to
increase with age in a linear manner. Liver injury should
be monitored on a regular basis. The place of TE in the
management of these children must be further defined.
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